Related Experiment Videos
[Adjuvant therapy in resectable non-small cell lung cancer]
Gan No Rinsho. Japan Journal of Cancer Clinics
|October 1, 1986
Summary
This study analyzed lung cancer treatment outcomes for 928 patients, finding a 43% 5-year survival rate. Chemotherapy improved survival for adenocarcinoma patients after surgery.
Area of Science:
- Oncology
- Thoracic Surgery
- Cancer Research
Context:
- Analysis of long-term treatment outcomes for lung cancer patients undergoing pulmonary resection.
- Data collected from a hospital tumor registry spanning 1952-1983.
- Inclusion of 928 patients with pathological TNM diagnosis for lung carcinoma.
Purpose:
- To evaluate the effectiveness of various treatment modalities for lung cancer at different stages.
- To identify factors influencing 5-year survival rates after surgical resection.
- To assess the impact of adjuvant therapies, including chemotherapy and irradiation.
Summary:
- The overall 5-year survival rate was 43% for the analyzed cohort.
- Survival rates varied significantly by stage: Stage I (77%), Stage II (54.7%), Stage III (17%), and Stage IV (4%).
- Chemotherapy demonstrated a 52% 5-year survival rate, outperforming other modalities like irradiation (29%) and radiochemotherapy (15%).
Impact:
- Postoperative chemotherapy showed survival benefits for adenocarcinoma patients who had curative surgery.
- Irradiation in patients with N2 lymph node involvement did not improve survival time.
- Findings contribute to optimizing lung cancer management strategies and treatment selection.